0001615774-18-005290.txt : 20180614 0001615774-18-005290.hdr.sgml : 20180614 20180614160620 ACCESSION NUMBER: 0001615774-18-005290 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180612 FILED AS OF DATE: 20180614 DATE AS OF CHANGE: 20180614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEDERMAN SETH CENTRAL INDEX KEY: 0001563420 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 18899211 MAIL ADDRESS: STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP STREET 2: 509 MADISON AVE., SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 1-800-849-7894 MAIL ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 4 1 s110815_form4.xml 4 X0306 4 2018-06-12 0 0001430306 Tonix Pharmaceuticals Holding Corp. TNXP 0001563420 LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK NY 10022 1 1 0 0 Chief Executive Officer Common Stock, $0.001 par value 2018-06-12 4 P 0 1000 4.37 A 16166 D Common Stock, $0.001 par value 2018-06-12 4 P 0 2000 4.37 A 20463 I By Lederman & Co., LLC Common Stock, $0.001 par value 22700 I By 401(k) plan Common Stock, $0.001 par value 45900 I By IRA account Common Stock, $0.001 par value 3100 I By spouse Common Stock, $0.001 par value 2.917 I By Leder Laboratories, Inc. Common Stock, $0.001 par value 2917 I By Starling Pharmaceuticals, Inc. Common Stock, $0.001 par value 3246 I By L&L Technologies, LLC Common Stock, $0.001 par value 5898 I By Targent Pharmaceuticals, LLC Reporting person may be deemed to be a control person of this entity. /s/ Seth Lederman 2018-06-14